Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN C PARKER

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1457345928
CMS profile
111752
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$21,819.25

251 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN C PARKER

NPI 1457345928 · CMS profile ID 111752

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN C PARKER, NPI 1457345928, CMS profile ID 111752. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN C PARKER, NPI 1457345928, CMS profile ID 111752. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN C PARKER, NPI 1457345928, CMS profile ID 111752, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–251 of 251 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1457345928?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

251 matching records · $21,819.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 251 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–251 of 251.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $8.2301/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695205119 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,819.25 251
PY2020 $27,416.59 170
PY2021 $21,682.45 188
PY2022 $14,015.93 156
PY2023 $36,168.25 192
PY2024 $33,806.19 166
PY2025 $70,399.78 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,283.60 7
PY2025 Principal investigator $1,754,233.74 60
PY2024 Recipient $35,760.20 6
PY2024 Principal investigator $615,212.88 39
PY2023 Recipient $834.01 1
PY2023 Principal investigator $135,727.02 32
PY2022 Recipient $530.00 1
PY2022 Principal investigator $246,139.52 36
PY2021 Recipient $1,623.24 4
PY2021 Principal investigator $596,905.04 313
PY2020 Recipient $1,480.28 5
PY2020 Principal investigator $355,554.95 61
PY2019 Principal investigator $212,752.19 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,587.00 12/31/2025 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534587
Principal investigator 1 Merck Sharp & Dohme LLC $449.60 12/31/2025 Non-covered Recipient Entity
PMG Research of Wilmington
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control No dispute reported 06/30/2026 1232918019
Principal investigator 1 Insulet Corporation $1,000.00 12/17/2025 Non-covered Recipient Entity
ACCELLACARE
Feasibility of Simplified Onboarding in Adults with Type 2 Diabetes using Automated Insulin Delivery No dispute reported 06/30/2026 1206962116
Principal investigator 1 ABBVIE INC. $48,629.70 12/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529298
Principal investigator 1 TOLMAR, INC. $132.30 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323287
Principal investigator 1 TOLMAR, INC. $81.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323291
Principal investigator 1 Insulet Corporation $3,235.00 11/19/2025 Non-covered Recipient Entity
ACCELLACARE
Feasibility of Simplified Onboarding in Adults with Type 2 Diabetes using Automated Insulin Delivery No dispute reported 06/30/2026 1206961976
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 11/11/2025 Non-covered Recipient Entity
Accellacare
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415408
Principal investigator 1 TOLMAR, INC. $3,769.20 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323273
Principal investigator 1 TOLMAR, INC. $1,549.80 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323276
Principal investigator 1 TOLMAR, INC. $602.10 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323279
Principal investigator 1 TOLMAR, INC. $1,204.20 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323283
Principal investigator 1 ABBVIE INC. $56,137.05 11/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522541
Principal investigator 1 PFIZER INC. $20,305.21 11/04/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228724014
Principal investigator 1 ABBVIE INC. $30,898.80 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514365
Principal investigator 1 Insulet Corporation $1,425.00 09/24/2025 Non-covered Recipient Entity
ACCELLACARE
Feasibility of Simplified Onboarding in Adults with Type 2 Diabetes using Automated Insulin Delivery No dispute reported 06/30/2026 1206961897
Principal investigator 1 PFIZER INC. $7,069.89 09/24/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228757552
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 09/09/2025 Non-covered Recipient Entity
Accellacare
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414712
Principal investigator 1 ABBVIE INC. $52,957.80 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509478
Principal investigator 1 Eli Lilly and Company $67,339.00 09/02/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187888960
Principal investigator 1 PFIZER INC. $9,926.37 08/26/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228786837
Principal investigator 1 ABBVIE INC. $81,881.55 08/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503239
Principal investigator 1 PFIZER INC. $7,775.63 08/05/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228766785
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,723.00 07/31/2025 Non-covered Recipient Entity
Accellacare
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412932
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,458.00 07/31/2025 Non-covered Recipient Entity
Accellacare
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225413182
Principal investigator 1 PFIZER INC. $350.00 07/18/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764986
Principal investigator 1 PFIZER INC. $12,209.59 07/15/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228724308
Principal investigator 1 ABBVIE INC. $27,278.10 07/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495219
Principal investigator 1 PFIZER INC. $22,339.83 06/26/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228776545
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,903.00 06/19/2025 Non-covered Recipient Entity
Accellacare
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412436
Principal investigator 1 Eli Lilly and Company $5.33 06/16/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187889512
Principal investigator 1 TOLMAR, INC. $6,909.30 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323195
Principal investigator 1 ABBVIE INC. $40,387.95 06/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488147
Principal investigator 1 TOLMAR, INC. $3,000.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323186
Principal investigator 1 TOLMAR, INC. $1,350.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323191
Principal investigator 1 PFIZER INC. $36,264.40 05/14/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228781749
Principal investigator 1 ABBVIE INC. $28,540.35 05/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483093
Principal investigator 1 PFIZER INC. $62,298.32 05/03/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228782515
Recipient Corcept Therapeutics $59.00 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162966
Recipient Corcept Therapeutics $71.74 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162974
Recipient Corcept Therapeutics $76.44 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162978
Recipient Corcept Therapeutics $98.62 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162983
Recipient Corcept Therapeutics $32.67 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162987
Recipient Corcept Therapeutics $573.36 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162962
Recipient Corcept Therapeutics $371.77 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214162970
Principal investigator 1 TOLMAR, INC. $7,688.25 04/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323182
Principal investigator 1 ABBVIE INC. $23,656.05 04/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202473132
Principal investigator 1 TOLMAR, INC. $4,179.60 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323173
Principal investigator 1 TOLMAR, INC. $1,094.85 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323177
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,079.00 03/27/2025 Non-covered Recipient Entity
Accellacare
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403889
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $123.00 03/13/2025 Non-covered Recipient Entity
Accellacare
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403887
Principal investigator 1 ABBVIE INC. $28,595.70 03/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202460641
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $9,626.00 03/06/2025 Non-covered Recipient Entity
Accellacare
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225403455
Principal investigator 1 ABBVIE INC. $33,280.20 02/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448019
Principal investigator 1 Eli Lilly and Company $2,073.62 01/31/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187887248
Principal investigator 1 Eli Lilly and Company $1,352.40 01/31/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187887788
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187889544
Principal investigator 1 Eli Lilly and Company $564,545.00 01/28/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187889502
Principal investigator 1 Eli Lilly and Company $5,161.39 01/27/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187887444
Principal investigator 1 Eli Lilly and Company $1,152.15 01/27/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187888958
Principal investigator 1 Eli Lilly and Company $1,470.16 01/27/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187889506
Principal investigator 1 Eli Lilly and Company $154,192.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187889100
Principal investigator 1 Eli Lilly and Company $38,404.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY No dispute reported 06/30/2026 1187890462
Principal investigator 1 PFIZER INC. $156.00 01/15/2025 Non-covered Recipient Entity
ACCELLACARE WILMINGTON
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228734354
Principal investigator 1 Eli Lilly and Company $41,626.00 01/07/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187887500
Principal investigator 1 Eli Lilly and Company $135,572.00 01/07/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187887504
Principal investigator 1 Eli Lilly and Company $42,163.00 01/07/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187888792